LONGJUMEAU, PARIS and MENLO PARK, Calif., Aug. 12 /PRNewswire/ -- PCAS, a worldwide leader in commercial scale pharmaceutical synthesis and fine and specialty chemical manufacturing, and Nanosyn, a leading US based pharmaceutical contract research provider of preclinical chemistry and biology services, announce the signing of a joint-venture agreement to operate PCAS-NANOSYN, LLC, a Good Manufacturing Practice (cGMP) kilolab in Santa Rosa, Northern California.
The newly created company, PCAS-NANOSYN, LLC, will enable PCAS and Nanosyn to satisfy a broader range of customer needs in the pharmaceutical and biotech marketplaces by offering fully integrated custom chemical services from discovery to commercialization.
"The formation of this JV with such a reputable partner as we have found in Nanosyn allows us to place critical preclinical and clinical trial API synthetic capabilities nearer to our clients in the US," said Christian Moretti, Chairman of PCAS, "It is an ideal next step in our strategy to continue growing our customer base in North America and builds on the success of our PCAS America marketing office in New Jersey."
The joint venture operation will provide services out of an FDA inspected facility in Santa Rosa, California, housing six (GMP) suites, two of which are certified as Class 10,000 clean rooms. PCAS-NANOSYN, LLC customers will further benefit from the significant chemical and analytical resources within the parent companies, and the ability to seamlessly transfer projects for larger scale to PCAS' network of four FDA inspected pilot and commercial scale plants in Europe.
"We are excited to offer this suite of cGMP solutions as a result of this partnership. For our clients, this is a natural extension of Nanosyn's highly successful discovery services into process development, scale-up, and supply of preclinical and cGMP clinical tri
|SOURCE PCAS-NANOSYN, LLC|
Copyright©2009 PR Newswire.
All rights reserved